Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials

被引:49
|
作者
Alosh, Mohamed [1 ]
Huque, Mohammad F. [2 ]
Bretz, Frank [3 ,4 ]
D'Agostino, Ralph B., Sr. [5 ]
机构
[1] US FDA, Div Biometr 3, Off Biostat, OTS,CDER, Silver Spring, MD 20993 USA
[2] US FDA, Off Biostat, OTS, CDER, Silver Spring, MD 20993 USA
[3] Novartis, Stat Methodol & Consulting, Basel, Switzerland
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria
[5] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
negative subgroup treatment effect; treatment-by-subgroup interaction; supportive subgroup findings; targeted subgroup; MULTIPLE END-POINTS; SEVERE SEPSIS; DESIGN; ENRICHMENT; ALPHA; CONSISTENCY; FRAMEWORK; EFFICACY; CANCER;
D O I
10.1002/sim.7167
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Clinical trials target patients who are expected to benefit from a new treatment under investigation. However, the magnitude of the treatment benefit, if it exists, often depends on the patient baseline characteristics. It is therefore important to investigate the consistency of the treatment effect across subgroups to ensure a proper interpretation of positive study findings in the overall population. Such assessments can provide guidance on how the treatment should be used. However, great care has to be taken when interpreting consistency results. An observed heterogeneity in treatment effect across subgroups can arise because of chance alone, whereas true heterogeneity may be difficult to detect by standard statistical tests because of their low power. This tutorial considers issues related to subgroup analyses and their impact on the interpretation of findings of completed trials that met their main objectives. In addition, we provide guidance on the design and analysis of clinical trials that account for the expected heterogeneity of treatment effects across subgroups by establishing treatment benefit in a pre-defined targeted subgroup and/or the overall population. Copyright (C) 2016 John Wiley & Sons, Ltd.
引用
收藏
页码:1334 / 1360
页数:27
相关论文
共 50 条
  • [31] Subgroup analyses in randomized clinical trials: Statistical and regulatory issues
    Grouin, JM
    Coste, M
    Lewis, J
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2005, 15 (05) : 869 - 882
  • [32] Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials
    Collignon, Olivier
    Gartner, Christian
    Haidich, Anna-Bettina
    Hemmings, Robert James
    Hofner, Benjamin
    Petavy, Frank
    Posch, Martin
    Rantell, Khadija
    Roes, Kit
    Schiel, Anja
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (05) : 1059 - 1067
  • [33] A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials
    Millen, Brian A.
    Dmitrienko, Alex
    Ruberg, Stephen
    Shen, Lei
    DRUG INFORMATION JOURNAL, 2012, 46 (06): : 647 - 656
  • [34] A Statistical Framework for Decision Making in Confirmatory Multipopulation Tailoring Clinical Trials
    Brian A. Millen
    Alex Dmitrienko
    Stephen Ruberg
    Lei Shen
    Drug information journal : DIJ / Drug Information Association, 2012, 46 : 647 - 656
  • [35] Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup
    Sugitani, Toshifumi
    Posch, Martin
    Bretz, Frank
    Koenig, Franz
    STATISTICS IN MEDICINE, 2018, 37 (24) : 3387 - 3402
  • [36] Subgroup analysis and interpretation for phase 3 confirmatory trials: White paper of the EFSPI/PSI working group on subgroup analysis
    Dane, Aaron
    Spencer, Amy
    Rosenkranz, Gerd
    Lipkovich, Ilya
    Parke, Tom
    PHARMACEUTICAL STATISTICS, 2019, 18 (02) : 126 - 139
  • [37] Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer
    Halabi, Susan
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (03) : 300 - 307
  • [38] A MISCELLANY OF STATISTICAL AND OTHER CONSIDERATIONS FOR CLINICAL-TRIALS
    MANTEL, N
    CONTROLLED CLINICAL TRIALS, 1980, 1 (01): : 3 - 11
  • [39] An investigator's introduction to statistical considerations in clinical trials
    Winter, Kathryn
    Pugh, Stephanie L.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (05) : 305 - 312
  • [40] Statistical Considerations in the Design of Biosimilar Cancer Clinical Trials
    Ahn, Chul
    Lee, Seung-Chun
    KOREAN JOURNAL OF APPLIED STATISTICS, 2011, 24 (03) : 495 - 503